B. Braun Renal Therapies Division Announces Availability of Adimea

BETHLEHEM, Pa., April 27 /PRNewswire/ -- The Renal Therapies Division of B. Braun Medical Inc. (B. Braun) has announced the U.S. introduction of Adimea™, an innovative process for real-time monitoring of dialysis effectiveness during treatment.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO )

Adimea, developed by B. Braun and already in use in Europe, is designed for use with B. Braun's Dialog+ Hemodialysis System, provides healthcare professionals with the information they need to give patients the optimal dialysis dose (Kt/V).

U.S. FDA-cleared, the Adimea process uses spectroscopy principles to measure dialysis efficiency by determining the reduction in the molar concentration of urinary excreted substances in the spent dialysate by transmitting an ultraviolet (UV) light source through the dialysate. The highly reliable and precise instrument allows the online determination and continual monitoring of current Kt/V values throughout the patient's entire treatment.  

"Adimea is a very important advancement in renal therapies," said Samuel Amory, Vice President, Renal Therapies Division for B. Braun Medical Inc. "It helps healthcare professionals give their patients an optimal dialysis dose and allows them to adjust treatment parameters for the benefit of patients even during treatment."  

Easy to use and efficient, Adimea requires the entry of only one patient parameter – the patient's weight before dialysis. It saves time by eliminating the determination and entry of the urea volume (V), which enables healthcare professionals to focus more attention on patient care.

For more information or to order Adimea, call 800-848-2066.

About B. Braun

B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise®" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.

Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals. For more information, call 800-227-2862, e-mail us at [email protected] or visit B. Braun at www.bbraunusa.com.

SOURCE B. Braun